Curamir Therapeutics, a Woburn, MA-based developer of miRNA-based cancer therapeutics, raised $10M in Series A funding.
The round was led by Delos Capital.
Curamir Therapeutics is a biotechnology company pioneering micro RNA (miRNA) based cancer therapeutics.
Incubated through a licensing collaboration with the State University of New York (SUNY) and co-founded by Dr. Jingfang Ju, Professor of Department of Pathology at Stony Brook University; Dr. James D. Watson, co-discoverer of the DNA structure and a 1962 Nobel Laureate; and Dr. Lan Bo Chen, Professor Emeritus of Pathology at Harvard Medical School and an Academician of the Academia Sinica of Taiwan, Curamir is developing innovative therapeutics based on its proprietary miRNA engineering platform and insights into cancer biology, aiming to address unmet needs to overcome drug resistance and toxicity associated with current oncology therapies.
Dr. Ju has more than 25 years of research expertise on chemoresistance in cancer research. His lab at SUNY studies miRNAs in cancer stem cell resistance, epithelial to mesenchymal transition, autophagy, and apoptosis in various cancers.
Dr. Watson is the co-discoverer of the DNA structure and the Nobel Laureate in 1962 in Physiology / Medicine. He also helped establish the Human Genome Project.
Dr. Lan Bo Chen is the author of over 250 publications. He founded several successful biotech companies and led the development or consulted for more than a dozen drugs and drug candidates.
FinSMEs
23/09/2019